KYNTRA BIO, INC.
No SEC Form 4 filings for $KYNB in the last 30 days.
See all $KYNB insider activity →Kyntra Bio appointed Andrew E. Singer to its board on October 1, 2026, replacing Maykin Ho, who resigned. Singer brings biopharma investment banking expertise. CEO Thane Wettig executed a new change-in-control agreement effective September 30, 2026.
KYNTRA BIO, INC. (KYNB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors SAN FRANCISCO, October 1, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the appointment of Andrew E. Singer, MBA to its Board of Directors as an independent director and member o
Oppenheimer maintained an Outperform rating and $35.00 price target for Kyntra Bio (NASDAQ:KYNB) after the company restructured its royalty financing agreement, reducing obligations to $65M from $125M. The company made a $42.6M payment, eliminating $60M in future obligations while retaining royalty economics. Kyntra Bio has a current ratio of 2.69 and is trading at $7.78, below analyst targets. Oppenheimer expects Phase 3 and Phase 2 data in 2026 and sees improved financial flexibility.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning KYNB (KYNTRA BIO, INC.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent KYNB coverage spans corporate actions, earnings and financial news.
Board change with new director bringing investment banking expertise.
Board change may affect strategic direction and investor perception.
The restructuring improves liquidity and reduces debt, supporting a higher valuation and potential upside.
Balance‑sheet de‑risking reduces future liabilities by ~$80M, likely supporting upside in the stock.
Positive earnings surprise with net income and strong cash position may boost short-term price; clinical data could drive longer-term upside.
AlphAI scores every news story that mentions KYNB with an AI model for sentiment and relevance, and aggregates insider trades from KYNTRA BIO, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kyntra Bio appointed Andrew E. Singer to its board on October 1, 2026, replacing Maykin Ho, who resigned. Singer brings biopharma investment banking expertise. CEO Thane Wettig executed a new change-in-control agreement effective September 30, 2026.
1 min readKYNTRA BIO, INC. (KYNB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors SAN FRANCISCO, October 1, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the appointment of Andrew E. Singer, MBA to its Board of Directors as an independent director and member o
1 min readOppenheimer maintained an Outperform rating and $35.00 price target for Kyntra Bio (NASDAQ:KYNB) after the company restructured its royalty financing agreement, reducing obligations to $65M from $125M. The company made a $42.6M payment, eliminating $60M in future obligations while retaining royalty economics. Kyntra Bio has a current ratio of 2.69 and is trading at $7.78, below analyst targets. Oppenheimer expects Phase 3 and Phase 2 data in 2026 and sees improved financial flexibility.
2 min readKYNTRA BIO, INC. (KYNB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation • Company reduces the maximum aggregate payments under its royalty financing agreement from $125 million to $65 million • Company accelerated payment of $42.6 mi
2 min readKyntra Bio (KYNB) reported Q2 2026 earnings with revenue of -$1.5M, net income of $12.0M, and $95.7M in cash. Clinical updates include FG-3246 Phase II enrollment and roxadustat Phase III plans. Management expects cash to last into 2028 and discussed potential partnerships for roxadustat.
3 min readKyntra Bio (KYNB) reported Q2 2026 revenue of -$1.5M, a net income of $12.0M, and $95.7M in cash. Clinical trials for FG-3246 in prostate cancer and roxadustat in MDS showed progress. Operating expenses rose to $16.1M. Management expects cash to last into 2028 and is evaluating partnership options for roxadustat.
2 min readKYNTRA BIO, INC. (KYNB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update • Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues
6 min readKYNTRA BIO, INC. (KYNB) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0000921299 false 0000921299 2026-06-12 2026-06-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12,
2 min readKyntra Bio, Inc. (NASDAQ:KYNB) published its Q1 2026 earnings call presentation on May 11, 2026. This slide deck accompanies the company's first-quarter financial results. The article was written by SA Transcripts, a team dedicated to publishing earnings call materials.
3 min read
